Omnia Education

Current and Emerging Approaches to Diagnose and Manage Hypoactive Sexual Desire Disorder

Current and Emerging Approaches to Diagnose and Manage Hypoactive Sexual Desire Disorder
RestartResume
ECHO™ A CME Self-Study Activity: Current and Emerging Approaches to Diagnose and Manage Hypoactive Sexual Desire Disorder

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Enhanced understanding of the pathophysiology of HSDD is changing the management of women who are affected. As therapeutic options become available, there is an acute need for clinicians to more proactively engage their female patients on the topic of sexual health, to manage them appropriately.

    This activity will discuss strategies to address barriers that inhibit the appropriate diagnosis and management of this condition. It will also inform on the current and emerging therapeutic modalities in the management of HSDD.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty: 
    David J. Portman, MD
    Director Emeritus, Columbus Center for Women’s Health Research
    Adjunct Instructor, Obstetrics and Gynecology
    The Ohio State University
    Columbus, OH

    Dr. Portman receives a salary from Sermonix Pharmaceuticals, consulting fees from AMAG Pharmaceuticals, Duchesnay, Endoceutics, Palatin, Sprout, and Therapeutics MD, is a speaker for AMAG Pharmaceuticals and Therapeutics MD, and has ownership interest in Sermonix Pharmaceuticals.   

    Reviewers/Content Planners/Authors:

    • Carole Drexel, PhD, CHCP has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Ashley Rosenthal has nothing to disclose.
    • Robert Schneider, MSW has nothing to disclose.
    • Lauren F.  Streicher, MD receives consulting fees from AMAG Pharmaceuticals, Inc. and has ownership interest in Sermonix Pharmaceuticals.  
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Define hypoactive sexual desire disorder.
    • Address barriers that inhibit the appropriate diagnosis and management of HSDD.
    • Identify the screening tools that allow for diagnosis of HSDD.
    • Identify current and emerging therapeutic modalities to manage HSDD.
  • Target Audience

    This activity is designed to meet the educational needs of obstetricians and gynecologists, family medicine physicians, internal medicine physicians, physician assistants, nurse practitioners, and certified nurse midwives.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by an independent educational grant from AMAG Pharmaceuticals, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Sign-up for the Omnia Education newsletters.
Comprehensive women’s health CME.

Better education for a better you.

* Required
Optional
Register

Join Omnia Education's community of women's health professionals.
Registration is free and easy.

Register Now